Trial NCT02824575

View at ClinicalTrials.gov 
Org. Study IDs: 2016-6488

Last trial update was posted on 2022-04-04

MeSH Interventions

Paclitaxel Rebastinib

MeSH Conditions

Breast Neoplasms Carcinoma

Other Conditions

Breast Adenocarcinoma Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Recurrent Breast Carcinoma Stage IV Breast Cancer

Stopping Reasons

Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID